PT  - JOURNAL ARTICLE
AU  - Campbell, Cori
AU  - Andersson, Monique
AU  - Ansari, M Azim
AU  - Moswela, Olivia
AU  - Misbah, Siraj A
AU  - Klenerman, Paul
AU  - Matthews, Philippa C
TI  - Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following Tocilizumab therapy: A systematic review to inform risk assessment in the COVID era
AID  - 10.1101/2021.03.22.21254128
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.22.21254128
4099  - http://medrxiv.org/content/early/2021/03/26/2021.03.22.21254128.short
4100  - http://medrxiv.org/content/early/2021/03/26/2021.03.22.21254128.full
AB  - Tocilizumab (TCZ), an IL-6 receptor antagonist, is used in the treatment of COVID. However, this agent carries a ‘black box’ warning for infection complications, which may include reactivation of tuberculosis (TB) or hepatitis B virus (HBV), or worsening of hepatitis C virus (HCV). Due to the pace of clinical research during the COVID pandemic, prospective evaluation of these risks has not been possible. We undertook a systematic review, generating mean cumulative incidence estimates for reactivation of HBV and TB at 3.3% and 4.3%. We could not generate estimates for HCV. These data derive from heterogeneous studies pre-dating the COVID outbreak, with differing epidemiology and varied approaches to screening and prophylaxis. We underline the need for careful individual risk assessment prior to TCZ prescription, and present an algorithm for clinical stratification. There is an urgent need for ongoing collation of safety data as TCZ therapy is used in COVID.KEY POINTS Use of tocilizumab treatment in COVID-19 may risk infective complications. We have undertaken a systematic literature review to assess the risks of reactivation of HBV and TB, generating mean estimates of 3.3% and 4.3% incidence, respectively.Competing Interest StatementThis work was supported by Wellcome (grant references 110110/Z/15/Z to PCM, 220171/Z/20/Z to MAA, and 109965MA to PK), Royal Society funding (MAA) and the Nuffield Department of Medicine, University of Oxford, and GlaxoSmithKline (GSK) (D.Phil funding to CC).Funding StatementThis work was supported by Wellcome (grant references 110110/Z/15/Z to PCM, 220171/Z/20/Z to MAA, and 109965MA to PK), Royal Society funding (MAA) and the Nuffield Department of Medicine, University of Oxford, and GlaxoSmithKline (GSK) (D.Phil funding to CC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/A, systematic review.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data presented were extracted from published articles identified via systematic review.